-Advertisement-
-Advertisement-
Home
Allergan announces positive phase 3 topline results for investigational eye drop for the treatment of presbyopia
Presbyopia
Allergan announces positive phase 3 topline results for investigational eye drop for the treatment of presbyopia
Allergan announced the phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety, and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint. In GEMINI 1, the primary endpoint was met with a statistically significant greater...
Read More-Advertisement-
-Advertisement-
-Advertisement-
Contact Info
© 2024 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved